Vimta Labs Ltd (VIMTALABS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Vimta Labs Ltd on NSE and BSE, with an AI summary of each filing.
Transcript of the FY / Q2 - 2026-27 Earnings / Investor Call held on 30th October 2026.
Transcript · 04 Nov 2026, 8:48 pm
Incorporation of a Wholly Owned Subsidiary in the United States of America (USA).
Others (Uncategorized) · 31 Oct 2026, 1:20 am
Vimta Labs Incorporates Wholly Owned Subsidiary Vimta Labs LLC in the USA Vimta Labs Limited has incorporated a wholly owned subsidiary, Vimta Labs LLC, in the United States on 24th Sep'26. Operating as a Contract Research Organization, the new entity will support the parent company's core operations, including preclinical studies, clinical trials, and analytical testing for pharmaceutical and biologics CRAD services. Vimta Labs holds a 100% equity stake via cash subscription, with a total initial investment of USD 8,500 to be infused in one or more tranches based on business requirements.
Audio Recording of the Earnings Call for Q2 FY 2026-27.
Audio / Video · 30 Oct 2026, 11:26 pm
Vimta Labs Releases Audio Recording for Q2 FY27 Earnings Call Vimta Labs Limited has made available the audio recording of its Q2 FY27 earnings and investor conference call held on 30th Oct'26. In compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, the company uploaded the recording to its official website for investor access.
Press Release - Unaudited Financial Results - 30th September 2026.
Press Release · 30 Oct 2026, 7:28 pm
Vimta Labs Delivers Steady Q2 FY27 Results With Total Income Up 9.9% YoY Vimta Labs reported Q2 FY27 total income of ₹1,149 Mn, rising 9.9% YoY and 1.8% QoQ, driven by core pharmaceutical and food testing alongside initial revenues from biologics CRAD services. EBITDA grew 10.5% YoY to ₹408 Mn, delivering a 35.5% margin, while PAT rose 3.5% YoY to ₹206 Mn with a 17.9% margin. Basic EPS reached ₹4.6. For H1 FY27, total income increased 11.8% YoY to ₹2,278 Mn and EBITDA advanced 13.2% YoY to ₹819 Mn with a 36.0% margin.
Investor Presentation - Q2 Results - FY 2026-27
Investor Presentation · 30 Oct 2026, 6:57 pm
Vimta Labs Reports Steady Q2 & H1 FY27 Performance with Strong Margins Vimta Labs reported Q2 FY27 total income of ₹1,149 Mn, up 9.9% YoY and 1.8% QoQ, with revenue from operations at ₹1,120 Mn. EBITDA reached ₹408 Mn (35.5% margin), rising 10.5% YoY, while PAT grew 3.5% YoY to ₹206 Mn (17.9% margin) with basic EPS of ₹4.6. For H1 FY27, total income stood at ₹2,278 Mn (+11.8% YoY), EBITDA at ₹819 Mn (36.0% margin, +13.2% YoY), and PAT reached ₹417 Mn (+7.3% YoY). Cash and equivalents totaled ₹701 Mn against total debt of ₹144.34 Mn.
Vimta Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 30 Oct 2026, 6:45 pm
Unaudited Financial Results for the 2nd Quarter and Half Year ended 30.09.2026.
Financial Result · 30 Oct 2026, 6:40 pm
Unaudited Financial Results for the 2nd Quarter and Half Year ended 30.09.2026.
Outcome · 30 Oct 2026, 6:34 pm
Vimta Labs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Million) ■ Revenue: 1,120 (+10.0% YoY | +2.7% QoQ) ■ EBITDA: 379 (+10.6% YoY | +1.5% QoQ) ■ EBITDA Margin (%): 33.8 (+21 bps YoY | -39 bps QoQ) ■ PAT: 206 (+3.5% YoY | -2.0% QoQ) ■ EPS (INR): 4.57 (+2.9% YoY | -1.9% QoQ)
Intimation of Schedule of Analyst/Investor Conference call.
Intimation · 30 Oct 2026, 2:30 pm
Vimta Labs Schedules Q2 FY27 Earnings Conference Call for 30th Oct'26 Vimta Labs Limited has scheduled an analyst and investor conference call on Friday, 30th Oct'26 at 2:30 PM IST, hosted by Systematix Institutional Equities. The call follows the announcement of the company’s unaudited financial results for the quarter and half-year ended 30th Sep'26 (Q2 FY27). Senior management—including Managing Director Harita Vasireddi, Executive Director Satya Sreenivas Neerukonda, and CFO Siva Rama Krishna Kambhampati—will represent the company to discuss business performance and financial outcomes. Primary domestic dial-ins include +91 22 6280 1297 and +91 22 7115 8198.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 30 Oct 2026, 5:30 am
Vimta Labs Limited has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 30 Oct 2026, 5:30 am
Vimta Labs Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation · 30 Oct 2026, 5:30 am
Vimta Labs Board Meeting Scheduled for 30th Oct'26 to Consider Q2 Results Vimta Labs Limited has scheduled a Board of Directors meeting on 30th Oct'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, in compliance with SEBI Insider Trading Regulations, the company's trading window closed on 1st Oct'26 and will remain shut until 48 hours post the announcement of the financial results.
Allotment of Employee Stock Options under "Vimta Labs Employee Stock Option Plan 2021".
Others (Uncategorized) · 16 Sept 2026, 9:17 pm
Vimta Labs Allots 12,955 Equity Shares Under ESOP Plan 2021 Vimta Labs Limited's ESOP Allotment Committee approved the allotment of 12,955 equity shares (face value ₹2 each) on 16th Sep'26 under the Vimta Labs Employee Stock Option Plan 2021 at an exercise price of ₹2 per share. Consequently, the company's paid-up equity share capital increased from ₹8,93,73,808 (4,46,86,904 shares) to ₹8,93,99,718 (4,46,99,859 shares). The newly allotted shares rank pari-passu with existing equity shares, and listing formalities are currently underway.
Intimation of Schedule of Analyst/ Institutional Investor Meet.
Intimation · 08 Sept 2026, 11:53 pm
Vimta Labs Schedules One-on-One Investor Meeting with Quant Mutual Fund Vimta Labs Limited announced a one-on-one virtual meeting with investment analyst Mr. Ankit Pandey (Fund Manager) from Quant Mutual Fund, scheduled for 11th Sep'26 at 2:00 PM IST. The stated agenda is to discuss and understand the company's business operations. The company confirmed that no unpublished price sensitive information (UPSI) will be shared during the interaction, in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Disclosure on Credit Rating.
Others (Uncategorized) · 03 Sept 2026, 12:36 am
CARE Ratings Reaffirms Vimta Labs' Debt Facilities with a Stable Outlook On 2nd Sep'26, CARE reaffirmed Vimta Labs' credit ratings at CARE A; Stable for long-term and CARE A1 for short-term bank facilities. The rating reflects Vimta's strong FY26 financial performance, driven by robust growth in pharmaceutical research. Total operating income reached ₹411.04 crore with impressive PBILDT and PAT margins of 35.26% and 18.86%, respectively. Vimta maintains a conservative capital structure with negligible 0.01x overall gearing and strong liquidity. Future growth is supported by a planned ₹60 crore FY27 capex targeting its upcoming Biologics segment commercialization.
Reply to the clarification regarding increase in volume.
Others (Uncategorized) · 01 Sept 2026, 6:38 pm
Vimta Labs Responds to BSE Query on Volume Increase In response to a BSE query dated 01 Sep'26 regarding increased trading volume, Vimta Labs has clarified it has not withheld any price-sensitive information. The company affirmed that all necessary disclosures under SEBI's Regulation 30 have been promptly made. Vimta Labs stated its belief that the movement in share price and volume is purely due to market-driven factors and is not attributable to any undisclosed company-specific events or announcements. The company has no further information to share regarding the matter.
The Exchange has sought clarification from Vimta Labs Ltd on September 01, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.
Others (Uncategorized) · 01 Sept 2026, 6:03 pm
Intimation of Schedule of Analyst/Institutional Investor Meet.
Intimation · 29 Aug 2026, 3:52 pm
Vimta Labs Schedules Meetings with Oppenheimer and Abakkus Asset Management Vimta Labs has scheduled one-on-one meetings to discuss business operations. Management will meet physically with Mr. Lukas Davies (Lead Investments) of Oppenheimer Generations Asia on 04th Sep'26. A virtual meeting is scheduled with Mr. Karan Doshi (Fund Manager) of Abakkus Asset Management on 09th Sep'26. The company confirmed that no unpublished price-sensitive information will be shared during these interactions.
Intimation of Schedule of Analyst/Institutional Investors Meet.
Intimation · 29 Aug 2026, 3:47 pm
Vimta Labs Schedules Meetings with Oppenheimer and Abakkus Asset Management Vimta Labs has scheduled two one-on-one meetings to discuss its business operations. The first is a physical meeting on 04th Sep'26 with Mr. Lukas Davies of Oppenheimer Generations Asia at Vimta's Life Sciences Facility. The second is a virtual meeting on 09th Sep'26 with Mr. Karan Doshi of Abakkus Asset Management. The company stated that no unpublished price-sensitive information will be shared during these interactions with the institutional investors.
Intimation on cyber security incident
Others (Uncategorized) · 21 Aug 2026, 9:01 pm
Vimta Labs Discloses Cybersecurity Incident with No Material Impact Vimta Labs reported a cybersecurity incident on 21 Aug '26, affecting part of its IT infrastructure. The company has initiated containment, engaged external experts for assessment, and started remediation. Critically, operations and customer delivery services have remained fully functional throughout the event. Management has stated that there has been no material impact on operations identified so far. A detailed assessment to determine the root cause and implement necessary remedial actions is currently underway. The company has committed to updating stakeholders on the progress.
Intimation of Schedule of Analyst Meeting.
Intimation · 29 Jul 2026, 12:06 am
Vimta Labs Schedules Analyst Meetings to Discuss Business Operations Vimta Labs Limited has scheduled virtual one-on-one meetings with institutional investors on 31st Jul'26 to discuss its business operations. The company will meet with Ms. Pragati Khadse, Sr. Portfolio Manager at Nine Rivers Capital, from 3:30 PM to 4:30 PM IST. A subsequent meeting will be held with Mr. Avnish Tiwari (CIO) and Mr. Avnish Burman (Sr. Investment Professional) from Vaikarya Change from 4:30 PM to 5:30 PM IST. No unpublished price-sensitive information will be shared.
Intimation of Schedule of Analyst Meeting.
Intimation · 29 Jul 2026, 12:02 am
Vimta Labs Schedules Meetings with Institutional Investors Vimta Labs Limited has scheduled virtual one-on-one meetings with institutional investors on 31st Jul'26 to discuss its business operations. The company will meet with Ms. Pragati Khadse, Sr. Portfolio Manager at Nine Rivers Capital, from 3:30 PM to 4:30 PM IST. This will be followed by a meeting with Mr. Avnish Tiwari (CIO) and Mr. Avnish Burman (Sr. Investment Professional) from Vaikarya Change, scheduled from 4:30 PM to 5:30 PM IST. No unpublished price-sensitive information will be shared.
Transcript - Q1 Earnings Conference Call- FY 2026-27
Transcript · 24 Jul 2026, 11:44 pm
Q1 - FY 2026-27 - Audio Recording of the Earnings Call.
Audio / Video · 20 Jul 2026, 11:43 pm
Vimta Labs Discloses Q1 FY27 Earnings Call Recording Vimta Labs has published the audio recording of its Q1 FY 2026-27 earnings and investor call held on 20th Jul'26. The release complies with SEBI (LODR) Regulations, 2015. The recording is accessible via a link on the company's website, providing investors and analysts with direct access to management discussions on quarterly performance and outlook. The disclosure was filed with both the BSE (Scrip: 524394) and NSE (Symbol: VIMTALABS).
Press Release - Unaudited Financial Results - 30.06.2026.
Press Release · 20 Jul 2026, 8:54 pm
Vimta Labs Reports Strong Q1 FY27 YoY Growth Vimta Labs reported solid Q1 FY27 results with total income rising 13.7% YoY to ₹1,129 Mn. EBITDA grew 16.0% YoY to ₹411 Mn, with the EBITDA margin expanding to 36.4% from 35.7% in Q1 FY26. Profit After Tax (PAT) increased 11.4% YoY to ₹210 Mn, resulting in a PAT margin of 18.6%. Basic EPS for the quarter was ₹4.7, up 11.0% YoY. The performance was driven by healthy traction in the Pharmaceutical Research and Testing Services business, offsetting headwinds in the Food Testing division.